Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 19.00
Low: 17.85
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing, supply & profit sharing agreement

1 Nov 2017 07:00

RNS Number : 1441V
OptiBiotix Health PLC
01 November 2017
 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Manufacturing, supply and profit sharing agreement with Knighton Foods

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a manufacturing and supply agreement with Knighton Foods, ("Knighton"). The agreement grants Knighton an exclusive licence to manufacture and supply OptiBiotix's SlimBiome® weight management technology in the United Kingdom, in return for 50% of the profit, with an agreed cost of manufacture and minimum sales price per kilogramme.

 

Knighton, a wholly owned subsidiary of Premier Foods plc, is a leading producer of a wide range of high quality, value adding, functional powdered foods, specialist ingredients and finished products, to some of the countries major supermarkets, high street coffee houses, and best-known household brands. Knighton's advanced powder technology was key to developing an improved version of SlimBiome®, providing enhanced solubility and better product presentation, greatly improving flavour and mouthfeel.

 

SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be supplied by Knighton as a specialised functional ingredient, into a wide range of finished products for use in the retail, vending, and ingredients sectors. Knighton will use their best endeavours to promote and expand the supply of SlimBiome®, bringing it to the attention of product innovation teams across their wide range of customers.

 

This agreement, with one of the UK's leading specialist ingredients suppliers, is an important step in optimising the supply chain by leveraging Knighton's purchasing power, manufacturing efficiencies and partner network to scale up the manufacture and supply of SlimBiome®.  This is an important step to meet the needs of major UK retailers and exports of SlimBiome®, and SlimBiome® containing products to Tata, and potential new partners, in the Iarge consumer markets of India and the USA.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Knighton Foods. We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome®. Their development work greatly improved SlimBiome's solubility, taste and mouthfeel whilst reducing the overall cost of manufacture. We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome® from partners worldwide."

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0883

Liam Murray

 

FinnCap (Broker)

 

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

About Knighton Foods www.knightonfoods.com

 

Knighton Foods, based in the U.K are a leading producer of high quality specialist powdered products. Their suite of processes includes, processing, blending and packaging capabilities ranging from portion controlled sachets to 1 ton bulk containers. 

Knighton's technical and R&D capabilities have been developed over 100+ years' and deliver value and functionality to ingredients and finished products, for use in the Retail, Out of Home, and Ingredients sectors. Examples of which can be found on the shelves of the UK's leading supermarkets in some of the most recognised consumer brands, and leading chains of fast food restaurants and coffee shops.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREFLFXDBFBFBX
Date   Source Headline
4th Jul 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSAgreement with global corporate for SweetBiotix®
21st Jun 20187:00 amRNSExclusive license agreement for LPLDL®
18th Jun 20187:00 amRNSManufacturing agreement with Morley Foods
14th Jun 20187:00 amRNSExercise of Options and Issue of Equity
11th Jun 20187:00 amRNSNotice of AGM
7th Jun 20187:00 amRNSUS launch of LPLDL® with Seed Health
31st May 20187:00 amRNSSweetBiotix® agreement with global dairy company
30th May 20187:00 amRNSPlacing and Issue of Equity
23rd May 20187:00 amRNSFinal Results
22nd May 20187:00 amRNSLP-LDL agreement for USA
18th May 20187:00 amRNSSlimBiome® wins award at Vitafoods 2018
16th May 20184:40 pmRNSHolding(s) in Company
16th May 20187:00 amRNSExclusive manufacturing and supply agreement
8th May 20187:00 amRNSLaunch of extended range of products at Vitafoods
1st May 20187:00 amRNSLP-LDL? news media interest in USA
30th Apr 20187:00 amRNSNotice of Results
24th Apr 20187:00 amRNSSlimBiome non-exclusive UK distribution agreement
19th Apr 20187:00 amRNSAppointment of Head of Online Sales and Marketing
18th Apr 20187:00 amRNSCholBiome exclusive distribution agreement
5th Apr 20187:00 amRNSNew patent filings for SweetBiotix
27th Mar 20187:00 amRNSScientific and commerical update
8th Mar 20187:00 amRNSLaunch of Slimbiome in Nutri-bites
6th Mar 20187:00 amRNSLPLDL® Exclusive European License Agreement
28th Feb 20187:00 amRNSOptiBiotix Capital Reorganisation
6th Feb 20187:00 amRNSExercise of warrant and issue of equity
1st Feb 20182:22 pmRNSDirector's dealing
30th Jan 20183:03 pmRNSExercise of warrant and issue of equity
25th Jan 201811:45 amRNSResult of Meeting
23rd Jan 20187:00 amRNSSweetBiotix® development: human taste studies
17th Jan 20187:00 amRNSPresentation of data at European Conference
8th Jan 20183:12 pmRNSShareholder Circular and Notice of General Meeting
8th Jan 20187:00 amRNSDirectorate Changes
14th Dec 20173:35 pmRNSExercise of warrant and issue of equity
12th Dec 20177:00 amRNSManufacturing, supply & profit sharing agreement
5th Dec 20177:00 amRNSProposed directorate changes
28th Nov 20177:00 amRNSCapital reorganisation
17th Nov 20173:06 pmRNSExercise of Warrant and Issue of Equity
8th Nov 20177:00 amRNSSlimBiome® commercial & product development update
1st Nov 20177:00 amRNSManufacturing, supply & profit sharing agreement
26th Oct 20177:00 amRNSPresentation of research
24th Oct 20177:00 amRNSLPLDL® supply agreement with Galenicum
4th Oct 20177:00 amRNSSuccessful launch of products at Supply Side West
19th Sep 20177:00 amRNSTechnical, regulatory & commercial update
13th Sep 20177:00 amRNSStrategic partnership with Bened Biomedical
11th Sep 201712:00 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSInvited to present at Expoquimia in Barcelona
6th Sep 20179:30 amRNSInvestor evening
5th Sep 20177:00 amRNSManufacturing Agreement with Tata Chemicals
1st Sep 20172:41 pmRNSExercise of Options and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.